Breast Surgery Practice Questions

Q: Which of the following is not a risk factor for breast carcinoma?

Early menopause. **Explanation:** The risk of breast carcinoma is primarily linked to the **cumulative lifetime exposure of breast tissue to estrogen**. Estrogen promotes the proliferation of mammary epithelial cells, increasing the likelihood of DNA mutations. **Why Early Menopause is the Correct Answer:** Early menopause (cessation of menstruation before age 45) is actually a **protective factor**, not a risk factor. It shortens the duration of the "estrogen window," thereby reducing the total lifetime exposure to ovarian hormones. Conversely, **late menopause** (after age 55) is a well-known risk factor. **Analysis of Incorrect Options:** * **Saturated Fatty Acids:** High dietary intake of saturated fats and obesity (especially post-menopausal) are linked to increased risk. In obese women, peripheral conversion of androstenedione to estrone in adipose tissue increases circulating estrogen levels. * **Nulliparous Women:** Women who have never carried a pregnancy to term have higher risk because they do not experience the hormonal "break" provided by pregnancy and lactation. Early first pregnancy (before age 20) is protective. * **Estrogen Unopposed by Progesterone:** Prolonged exposure to estrogen without the balancing effect of progesterone (e.g., Hormone Replacement Therapy or early menarche) stimulates ductal hyperplasia, increasing malignancy risk. **High-Yield Clinical Pearls for NEET-PG:** * **The "Estrogen Window" Concept:** Risk increases with early menarche ( 55 years). * **BRCA Mutations:** BRCA1 (Chromosome 17) and BRCA2 (Chromosome 13) are the most significant genetic risk factors. * **Breastfeeding:** For every 12 months of breastfeeding, the relative risk of breast cancer decreases by approximately 4.3%. * **Atypical Hyperplasia:** Finding atypical ductal or lobular hyperplasia on biopsy increases risk by 4–5 times.

Q: Which of the following is NOT a risk factor for increased incidence of relapse in stage I carcinoma of the breast?

Decreased Her-2/neu oncogene expression. **Explanation:** In breast cancer management, prognostic factors are used to predict the risk of recurrence and guide adjuvant therapy. The question asks for the factor that is **NOT** associated with an increased risk of relapse. **1. Why Option D is Correct:** The **Her-2/neu (c-erbB2)** oncogene is a transmembrane tyrosine kinase receptor. **Increased expression (amplification)** of this gene is associated with aggressive tumor behavior, higher grade, and a significantly increased risk of relapse. Therefore, **decreased expression** would theoretically imply a better prognosis or a baseline risk, rather than an increased risk of relapse. **2. Analysis of Incorrect Options (Risk Factors for Relapse):** * **A. Negative ER/PR status:** Estrogen and Progesterone receptor-negative tumors are generally more aggressive, have a higher histological grade, and do not respond to endocrine therapies (like Tamoxifen), leading to a higher incidence of relapse. * **B. High S-phase fraction:** This is a measure of cellular proliferation (the percentage of cells replicating DNA). A high S-phase fraction indicates a rapidly dividing, aggressive tumor with a higher likelihood of recurrence. * **C. Aneuploidy:** DNA aneuploidy (abnormal amount of DNA) is a marker of genetic instability. Aneuploid tumors have a worse prognosis compared to diploid tumors in Stage I breast cancer. **Clinical Pearls for NEET-PG:** * **Most important prognostic factor** for breast cancer: Number of axillary lymph nodes involved. * **Most important prognostic factor in Node-Negative (Stage I) disease:** Tumor size. * **Triple Negative Breast Cancer (TNBC):** Lacks ER, PR, and Her-2 expression; carries the worst prognosis among molecular subtypes. * **Luminal A:** (ER/PR +, Her-2 -, low Ki-67) has the best prognosis.

Q: Triple examination of a breast lump includes all of the following except?

Excision biopsy. The **Triple Assessment** (or Triple Examination) is the gold standard protocol for evaluating a breast lump to ensure maximum diagnostic accuracy (approaching 99%). It consists of three components: Clinical, Radiological, and Pathological. ### 1. Why "Excision Biopsy" is the Correct Answer Triple assessment is designed as a **non-invasive or minimally invasive** diagnostic tool to avoid unnecessary surgery. **Excision biopsy** is a surgical procedure where the entire lump is removed; it is considered the "gold standard" for definitive diagnosis but is **not** part of the initial triple assessment. If the triple assessment is concordant (all three tests suggest the same diagnosis), the need for an excision biopsy is often bypassed. ### 2. Analysis of Other Options * **Clinical Examination (Option A):** This is the first step, involving a detailed history and physical examination (inspection and palpation) of the breast and axilla. * **Mammography (Option D):** This represents the **Radiological** component. In women >35 years, mammography is preferred; in women <35 years, Ultrasound (USG) is preferred due to dense breast tissue. * **FNAC (Option C):** This represents the **Pathological/Cytological** component. While Core Needle Biopsy (CNB) is now increasingly preferred over FNAC (as it provides tissue architecture and receptor status), both fall under the pathological arm of the triple assessment. ### 3. Clinical Pearls for NEET-PG * **Concordance:** If all three components of the triple assessment are benign, the negative predictive value is **>99%**. * **Sequence:** The standard sequence is Clinical → Imaging → Pathology. * **Age Cut-off:** For radiological assessment, use **USG for 35 years**. * **Core Needle Biopsy (CNB):** It is superior to FNAC because it can differentiate between *in-situ* and invasive carcinoma and allows for IHC (ER/PR/HER2neu) testing.

Q: All of the following structures are presented in the Medical Research Methodology (MRM) except?

Nipple. **Explanation:** The question refers to **Modified Radical Mastectomy (MRM)**, the standard surgical procedure for operable breast cancer. The primary goal of MRM is the removal of the entire breast tissue (including the nipple-areola complex and the fascia of the pectoralis major) along with a formal Level I and II axillary lymph node dissection. **Why "Nipple" is the correct answer:** In a standard MRM (specifically the **Auchincloss** or **Patey** modifications), the **nipple-areola complex is always sacrificed** as part of the elliptical skin incision to ensure oncological safety. Therefore, it is not "preserved" or "present" in the surgical field at the end of the procedure. **Analysis of Incorrect Options:** * **Axillary Vessels:** These form the superior boundary of the axillary dissection. While the axillary vein is skeletonized to remove associated lymph nodes, the vessels themselves are preserved. * **Bell’s Nerve (Long Thoracic Nerve):** This nerve supplies the Serratus Anterior muscle. It must be identified and preserved during axillary clearance to prevent "winging of the scapula." * **Cephalic Vein:** This vein runs in the deltopectoral groove. It serves as an important anatomical landmark for the superior limit of the dissection and is preserved. **High-Yield Clinical Pearls for NEET-PG:** 1. **Auchincloss Modification:** Removes breast + Level I & II nodes; preserves Pectoralis major and minor. 2. **Patey Modification:** Removes Pectoralis minor to facilitate Level III node clearance. 3. **Nerves at risk during MRM:** * **Long Thoracic Nerve (Bell’s):** Injury leads to Winging of Scapula. * **Thoracodorsal Nerve:** Supplies Latissimus Dorsi; injury weakens adduction/internal rotation. * **Intercostobrachial Nerve:** Most commonly injured nerve; leads to numbness of the inner arm.

Q: What is the surgical treatment for periductal mastitis?

Hadfield's operation. **Explanation:** **Periductal mastitis** (also known as Zuska’s disease or plasma cell mastitis) is a chronic inflammatory condition characterized by the inflammation and dilation of the subareolar lactiferous ducts. It is strongly associated with **smoking**. 1. **Why Option A is correct:** **Hadfield’s operation** (Total Subareolar Breast Duct Excision) is the definitive surgical treatment for recurrent periductal mastitis or chronic mammary fistulae. The procedure involves the complete excision of all the major lactiferous ducts. Since the pathology resides in the diseased ducts, removing the entire ductal system from the base of the nipple effectively prevents recurrence. 2. **Why other options are incorrect:** * **Patey’s Mastectomy:** This is a Modified Radical Mastectomy (MRM) that involves removing the breast tissue and axillary lymph nodes while preserving the Pectoralis major muscle but sacrificing the Pectoralis minor. It is indicated for **breast cancer**, not benign inflammatory conditions. * **Modified Radical Mastectomy (MRM):** This is the standard surgical treatment for **operable breast carcinoma**. It is far too invasive for a benign condition like periductal mastitis. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factor:** Smoking is the single most important etiological factor (causes squamous metaplasia of the duct lining). * **Clinical Presentation:** Often presents as a subareolar mass, nipple discharge (thick/creamy), or a periareolar abscess/fistula. * **Management:** Initial treatment involves antibiotics (covering anaerobes like *Bacteroides*) and abscess drainage. Surgery (Hadfield’s) is reserved for chronic or recurrent cases. * **Differential Diagnosis:** Must be distinguished from mammary duct ectasia (which typically affects older, post-menopausal women and is not necessarily linked to smoking).

Q: Ipsilateral supraclavicular lymph nodes are positive in a patient with Ca Breast. What is the clinical stage?

Stage III C. ### Explanation The clinical staging of breast cancer follows the **AJCC TNM Staging System (8th Edition)**. The presence of positive **ipsilateral supraclavicular lymph nodes** is classified as **N3c** nodal involvement. **1. Why Stage III C is Correct:** According to the TNM classification, any **N3** disease (which includes metastasis to ipsilateral infraclavicular, internal mammary, or supraclavicular nodes) automatically categorizes the patient into **Stage III C**, regardless of the tumor size (T), provided there is no distant metastasis (M0). Specifically: * **N3a:** Ipsilateral infraclavicular nodes. * **N3b:** Ipsilateral internal mammary nodes + axillary nodes. * **N3c:** Ipsilateral supraclavicular nodes. **2. Why Other Options are Incorrect:** * **Stage II:** This stage involves smaller tumors (T1-T2) with limited mobile axillary nodes (N0-N1). Supraclavicular involvement is too advanced for this category. * **Stage III B:** This stage is defined by **T4** status (tumor involving the chest wall or skin, including inflammatory breast cancer) with N0-N2 nodes. It does not include N3 nodal status. * **Stage IV:** This represents **distant metastasis (M1)**. While supraclavicular nodes were once considered M1 (in older classifications), they are now classified as **regional** nodes (N3c). Stage IV would require spread to the lungs, bones, liver, or contralateral supraclavicular nodes. **High-Yield Clinical Pearls for NEET-PG:** * **Regional vs. Distant:** Ipsilateral supraclavicular nodes = **N3c (Stage IIIC)**; Contralateral supraclavicular nodes = **M1 (Stage IV)**. * **Internal Mammary Nodes:** If detected clinically, they are N3b; if detected only by sentinel node biopsy (microscopic), they are N1b. * **Sentinel Lymph Node Biopsy (SLNB):** The investigation of choice for clinically N0 axilla. * **Isolated Tumor Cells (ITC):** Defined as clusters <0.2 mm or <200 cells; they are staged as pN0(i+).

Q: Which of the following is the most significant risk factor for developing breast cancer?

Atypical ductal hyperplasia. **Explanation:** The risk of developing invasive breast cancer is categorized based on the histological findings of a breast biopsy. This question tests the ability to differentiate between non-proliferative, proliferative without atypia, and proliferative with atypia lesions. **Why Atypical Ductal Hyperplasia (ADH) is correct:** ADH and Atypical Lobular Hyperplasia (ALH) are both "proliferative lesions with atypia." These carry the highest relative risk (RR) among the options provided, typically **4.0 to 5.0 times** the risk of the general population. Between the two, ADH is often clinically prioritized as it shares genetic and morphologic features with low-grade DCIS, representing a direct precursor in the neoplastic continuum. **Analysis of Incorrect Options:** * **A. Sclerosing Adenosis:** This is a "proliferative lesion without atypia." It carries a low risk, with a RR of approximately **1.5 to 2.0**. * **B. Nulliparity:** This is a reproductive risk factor. While significant, its RR is relatively low (approx. **1.2 to 1.7**) compared to biopsy-proven cellular atypia. * **C. Atypical Lobular Hyperplasia:** While ALH also carries a high RR (4.0–5.0), in standardized surgical exams, ADH is frequently cited as the most significant histological marker of future risk among these choices due to its closer association with subsequent ductal carcinoma. **NEET-PG High-Yield Pearls:** 1. **Highest Risk Factor Overall:** A positive **BRCA1/BRCA2** mutation (RR >10). 2. **RR 1.5–2.0 (No Atypia):** Sclerosing adenosis, intraductal papilloma, radial scar, and moderate/florid hyperplasia. 3. **RR 4.0–5.0 (With Atypia):** ADH and ALH. 4. **RR 8.0–10.0:** Lobular Carcinoma in Situ (LCIS) and Ductal Carcinoma in Situ (DCIS). 5. **Gail Model:** The most commonly used clinical tool to estimate individual breast cancer risk.

Q: Which of the following conditions, as seen on Fine Needle Aspiration Cytology (FNAC), is most likely to appear malignant in a breast aspirate?

Intraductal Carcinoma in situ. **Explanation:** The core challenge in breast cytology is distinguishing between high-grade benign lesions and low-grade malignant ones. **Intraductal Carcinoma in situ (DCIS)** is the correct answer because it represents a pre-invasive malignant proliferation of epithelial cells. On FNAC, DCIS often yields highly cellular aspirates with significant nuclear pleomorphism, prominent nucleoli, and necrosis (especially in the comedo subtype). These features mimic invasive carcinoma, making it the most "malignant-looking" entity among the choices. **Analysis of Options:** * **Fibroadenoma:** While it can be hypercellular, it typically shows a characteristic "biphasic" pattern: cohesive "staghorn" clusters of ductal cells and numerous background "naked" bipolar nuclei. These features are hallmarks of benignity. * **Fibroadenosis (Fibrocystic changes):** This is a benign condition. Aspirates show low cellularity, apocrine metaplasia, and fragments of fibrous stroma without significant cytologic atypia. * **Simple Cyst:** FNAC usually yields only clear or straw-colored fluid with a few degenerated epithelial cells or macrophages. It lacks the cellular density and atypia required to appear malignant. **NEET-PG High-Yield Pearls:** * **Triple Assessment:** The gold standard for breast lump diagnosis includes Clinical Examination, Imaging (Mammography/USG), and Pathology (FNAC/Biopsy). * **FNAC vs. Core Needle Biopsy (CNB):** FNAC cannot distinguish between DCIS and invasive carcinoma because it lacks architectural context (basement membrane integrity). CNB is now preferred for suspicious lesions. * **Cribriform Pattern:** Often associated with low-grade DCIS. * **Comedo Necrosis:** A high-grade feature of DCIS that strongly mimics invasive cancer on cytology.

Q: According to the TNM staging system, what stage is assigned to breast carcinoma with positive bilateral supraclavicular lymph nodes?

M1. **Explanation:** The correct answer is **M1**. In the AJCC TNM staging system for breast cancer, the classification of regional lymph nodes is strictly anatomical. **1. Why M1 is correct:** According to the TNM staging, **ipsilateral** (same side) supraclavicular lymph nodes are classified as **N3c** (Stage IIIC). However, any involvement of **contralateral** (opposite side) lymph nodes—including supraclavicular, internal mammary, or axillary nodes—is considered distant metastasis. Therefore, **bilateral** supraclavicular involvement implies that the contralateral side is affected, automatically upgrading the stage to **M1 (Stage IV)**. **2. Why other options are incorrect:** * **N3a:** Refers to metastasis in ipsilateral infraclavicular lymph node(s). * **N3b:** Refers to metastasis in ipsilateral internal mammary lymph node(s) in the presence of axillary node involvement. * **N3c:** Refers to metastasis in **ipsilateral** supraclavicular lymph node(s). While the question mentions supraclavicular nodes, the "bilateral" nature moves it out of the "N" category into the "M" category. **Clinical Pearls for NEET-PG:** * **Ipsilateral Supraclavicular Nodes:** These were once considered M1 but were reclassified to **N3c** because aggressive local treatment (Radiotherapy/Surgery) can still offer a chance at cure. * **Contralateral Nodes:** Always signify **M1** disease. * **Sentinel Lymph Node Biopsy (SLNB):** The gold standard for axillary staging in clinically N0 (node-negative) patients. * **Most common site of distant metastasis:** Bone (specifically the spine due to Batson’s plexus).

Q: Which of the following markers increases the risk of recurrent carcinoma breast?

Ca 27-29. **Explanation:** The correct answer is **Ca 27-29**. **1. Why Ca 27-29 is correct:** Cancer Antigen 27-29 (Ca 27-29) is a highly specific tumor marker for breast carcinoma. It is a soluble form of the **MUC1 gene product** (mucin). In clinical practice, it is primarily used to monitor patients previously treated for Stage II or III breast cancer. An elevation in Ca 27-29 levels is often the first sign of **recurrence or metastasis**, frequently predating clinical or radiological evidence by several months. Along with **CA 15-3**, it is considered the standard marker for monitoring treatment response and disease progression in breast cancer. **2. Why the other options are incorrect:** * **Ca 125:** This is the primary marker for **Ovarian Cancer** (specifically epithelial types). While it can be elevated in various inflammatory conditions (endometriosis, PID), it is not a specific marker for breast cancer recurrence. * **Ca 19-9:** This is the gold-standard marker for **Pancreatic Adenocarcinoma** and is also associated with hepatobiliary and gastric cancers. * **PSA (Prostate-Specific Antigen):** This is a highly specific marker for **Prostate Cancer** screening and monitoring. **High-Yield Clinical Pearls for NEET-PG:** * **CA 15-3 and CA 27-29:** Both are MUC1 markers used for breast cancer. CA 27-29 is generally considered more sensitive than CA 15-3. * **CEA (Carcinoembryonic Antigen):** Also used in breast cancer monitoring, though it is more classically associated with Colorectal Cancer. * **Triple Negative Breast Cancer (TNBC):** These tumors often do not produce significant amounts of these markers, making imaging more critical for follow-up. * **HER2/neu:** While a prognostic marker and therapeutic target, it is not typically used as a "serum tumor marker" for recurrence in the same way as CA 27-29.

Question 1

Which of the following is not a risk factor for breast carcinoma?

Accepted Answer

Early menopause

Answer

Saturated fatty acids

Answer

Nulliparous women

Answer

Estrogen unopposed by progesterone

Question 2

Which of the following is NOT a risk factor for increased incidence of relapse in stage I carcinoma of the breast?

Accepted Answer

Decreased Her-2/neu oncogene expression

Answer

Negative estrogen/progesterone receptor status

Answer

High S phase fraction

Answer

Aneuploidy

Question 3

Triple examination of a breast lump includes all of the following except?

Accepted Answer

Excision biopsy

Answer

Clinical examination

Answer

Fine Needle Aspiration Cytology (FNAC)

Answer

Mammography

Question 4

All of the following structures are presented in the Medical Research Methodology (MRM) except?

Accepted Answer

Nipple

Answer

Axillary vessels

Answer

Bell's nerve

Answer

Cephalic vein

Question 5

What is the surgical treatment for periductal mastitis?

Accepted Answer

Hadfield's operation

Answer

Patey's mastectomy

Answer

Modified radical mastectomy

Answer

None of the above

Question 6

Ipsilateral supraclavicular lymph nodes are positive in a patient with Ca Breast. What is the clinical stage?

Accepted Answer

Stage III C

Answer

Stage II

Answer

Stage III B

Answer

Stage IV

Question 7

Which of the following is the most significant risk factor for developing breast cancer?

Accepted Answer

Atypical ductal hyperplasia

Answer

The presence of sclerosing adenosis

Answer

Nulliparity

Answer

Atypical lobular hyperplasia

Question 8

Which of the following conditions, as seen on Fine Needle Aspiration Cytology (FNAC), is most likely to appear malignant in a breast aspirate?

Accepted Answer

Intraductal Carcinoma in situ

Answer

Fibroadenoma

Answer

Fibroadenosis

Answer

Simple cyst

Question 9

According to the TNM staging system, what stage is assigned to breast carcinoma with positive bilateral supraclavicular lymph nodes?

Accepted Answer

M1

Answer

N3a

Answer

N3b

Answer

N3c

Question 10

Which of the following markers increases the risk of recurrent carcinoma breast?

Accepted Answer

Ca 27-29

Answer

Ca 125

Answer

Ca 19-9

Answer

PSA

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?